Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $445.0 million.

  • Indivior Pharmaceuticals' Cash & Equivalents rose 5451.39% to $445.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.0 million, marking a year-over-year increase of 5451.39%. This contributed to the annual value of $319.0 million for FY2024, which is 5878.55% down from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Cash & Equivalents stood at $445.0 million, which was up 5451.39% from $510.0 million recorded in Q2 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Cash & Equivalents peaked at $1.1 billion during Q4 2021, and registered a low of $248.0 million during Q1 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $510.0 million (2025), whereas its average is $613.5 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Cash & Equivalents plummeted by 6795.87% in 2024 and then surged by 6887.42% in 2025.
  • Indivior Pharmaceuticals' Cash & Equivalents (Quarter) stood at $1.1 billion in 2021, then decreased by 29.76% to $774.0 million in 2022, then plummeted by 59.17% to $316.0 million in 2023, then rose by 0.95% to $319.0 million in 2024, then skyrocketed by 39.5% to $445.0 million in 2025.
  • Its last three reported values are $445.0 million in Q3 2025, $510.0 million for Q2 2025, and $372.0 million during Q1 2025.